scout

Joleen Hubbard, MD, Mayo Clinic

Articles by Joleen Hubbard, MD, Mayo Clinic

Preferences for Second-Line Therapy for mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

Drs Cathy Eng and Joleen M. Hubbard explain how patients with metastatic colon cancer typically respond to initial treatment and describe the factors that impact second-line treatment decisions.

Colorectal Cancer in a Younger Population

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

Cathy Eng, MD, FACP, FASCO, of Vanderbilt-Ingram Cancer Center reacts to the increasing rate of colorectal cancer among the younger population and highlights topics that apply specifically to counseling younger patients.

Initial Strategies for Assessing and Treating mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

Experts in gastrointestinal oncology highlight their approaches to assessing patients with newly diagnosed metastatic colorectal cancer and explain the variables that factor into first-line treatment decisions.